Oramed Pharmaceuticals Inc. (ORMP)
Healthcare · NCM
Fundamentals
Valuation and ratings
Oramed Pharmaceuticals Inc. trades at USD4.03, which is 124% below the USD9.02 our discounted cash flow model puts on the business. On that measure alone it screens as undervalued, though a DCF is an argument rather than a measurement, and the market is frequently right about why something is cheap.
Our moat model scores it 30 out of 100, which is little in the way of a moat. A moat is a structural reason competitors cannot take the profits away, and it matters more to a long holding period than any single quarter's numbers do.
It changes hands at 1.5 times earnings. Be careful reading that in isolation: for a cyclical business a low P/E arrives at the top of the cycle, when profits are peaking and about to fall, which is exactly when the shares look cheapest and are not.
ORMP dividend history
Dividends per share by year
| Year | Total per share | Payments |
|---|---|---|
| 2026 (year to date) | USD0.250 | 1 |
Split-adjusted amounts in the listing currency, grouped by the calendar year of the ex-dividend date, from the filed record. Growth and streak figures compare complete years only.
ORMP earnings and analyst estimates
Estimates are the published analyst consensus and move often. An earnings date is scheduled, not certain, and a share tends to reprice most violently on the day itself.
About Oramed Pharmaceuticals Inc.
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes. The company has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York, New York.
ORMP passes 6 of our 30 screens today
Each screen prints the exact criteria it used, and the circumstances in which it is wrong.
Super investor ownership
5 of the funds we track reported a position in their latest SEC 13F filing. Largest first:
- Marshall Wace, MARSHALL WACE, LLP$882.7K · 0.0% of book
- Renaissance Technologies, RENAISSANCE TECHNOLOGIES LLC$502.2K · 0.0% of book
- Ken Griffin, CITADEL ADVISORS LLC$335.3K · 0.0% of book
- Steve Cohen, Point72 Asset Management, L.P.$88.6K · 0.0% of book
- Israel Englander, MILLENNIUM MANAGEMENT LLC$54.5K · 0.0% of book
A word of warning on reading these figures: a 13F reports the market value of a holding, so a fund that traded nothing at all still appears to have sold when the price fell. We found 102 companies where the standard reading gives the opposite answer. Only the share count is honest.
Common questions
Is Oramed Pharmaceuticals Inc. (ORMP) undervalued?
Against our discounted cash flow estimate of USD9.02, ORMP at USD4.03 is 124% below fair value. That is one model's answer, not a recommendation, and most of a DCF's output sits in a terminal value nobody can forecast.
Which funds own ORMP?
5 of the institutions we track reported a position in ORMP in their most recent SEC 13F filing. A 13F is filed up to 45 days after quarter end, so it tells you what a fund held then, not what it holds now.
What is ORMP's P/E ratio?
ORMP trades at 1.5 times earnings. A low P/E is not automatically cheap: on a cyclical company it is usually a warning that earnings are at a peak.
Does Oramed Pharmaceuticals Inc. (ORMP) pay a dividend?
Yes. Oramed Pharmaceuticals Inc. yields 6.20% at the current share price. It has paid USD0.250 per share over the trailing twelve months. A dividend is declared by the board and can be cut at any time; a yield is a fact about the current price, not a promise.
When does ORMP report earnings next?
Oramed Pharmaceuticals Inc. is scheduled to report on 14 Aug 2026. Companies move earnings dates, so read it as scheduled rather than certain.
The full research page for ORMP, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.